TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02599766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: animal assisted therapy
Description: physiotherapy, speech therapy and occupational therapy in the presence of an animal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Description: standard physiotherapy, standard speech therapy and standard occupational therapy
Study: NCT02416635

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Study: NCT03013842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raydiant Oximetry Sensor System
Description: Administration of Fetal Oximetry Probe on 36 weeks or greater pregnant women
Study: NCT02915861

Intervention type: OTHER
Intervention: Non-invasive eschar samples + blood
Description: EXPa (n=12) will have blood and non-invasive eschar samples collected (consent to study, declined biopsy).

Intervention type: OTHER
Intervention: Non-invasive eschar samples+eschar biopsy+blood
Description: EXPb (n=12) will have blood, non-invasive eschar samples, and an eschar biopsy collected (consent to study, draining LN inaccessible).

Intervention type: OTHER
Intervention: Non-invasive eschar samples+eschar biopsy+lymph node fine-needle aspiration biopsy+blood
Description: EXPc (n=12) will have blood, non-invasive eschar samples, eschar biopsy, and LN FNA collected (consent to study, draining LN accessible).

Intervention type: OTHER
Intervention: Blood+Skin sample
Description: Controls (EXC, n=12) are healthy individuals, attending hospital for elective/minor surgery or treatment of minor skin injury, and normally reside in a scrub typhus endemic region. Blood and a skin sample will be collected at baseline only.
Study: NCT02552355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily administration of matching placebo during a 12 week exercise training program.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Daily administration of matching placebo during a 12 week exercise training program.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate Beverage
Description: Supervised aerobic exercise 3 days per week followed by a carbohydrate drink
Study: NCT03818659

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Guided M.A.P. BP Improvement Program
Description: Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full Support M.A.P. BP Improvement Program
Description: Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control.
Study: NCT02552355

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate Beverage
Description: Supervised aerobic exercise 3 days per week followed by a carbohydrate drink
Study: NCT01147549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C14]AZD9668
Description: Oral Solution 60 mg Single Dose
Study: NCT04311619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]UCB-J radiotracer
Description: I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein per injection
Study: NCT02552355

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Beverage
Description: Supervised aerobic exercise 3 days per week followed by a protein drink

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Beverage
Description: Supervised aerobic exercise 3 days per week followed by a protein drink
Study: NCT02935231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: 1-week free NRT (gum/patch) plus a card containing instruction and potential side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: 1-week free NRT (gum/patch) plus a card containing instruction and potential side effects.
Study: NCT04473261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine Complex
Description: Iodine Complex capsule (200mg) will be given three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine Complex
Description: Iodine Complex syrup form (40ml) will be given three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Empty capsule will be given as placebo
Study: NCT02935231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal Cessation Advice (MCA)
Description: Brief smoking cessation advice using AWARD model. AWARD: (1) Ask smoking habit; (2) Warn about smoking risk; (3) Advice to quit as soon as possible; (4) Refer to smoking cessation service; and (5) Do-it-again: if relapse/fail.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal Cessation Advice (MCA)
Description: Brief smoking cessation advice using AWARD model. AWARD: (1) Ask smoking habit; (2) Warn about smoking risk; (3) Advice to quit as soon as possible; (4) Refer to smoking cessation service; and (5) Do-it-again: if relapse/fail.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health warning leaflet
Description: An A4 double-side color leaflet containing shocking pictures of diseases associated with smoking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health warning leaflet
Description: An A4 double-side color leaflet containing shocking pictures of diseases associated with smoking.
Study: NCT03716323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediate premolar implant with xenograft and allograft
Description: * A peritome will be used for atraumatic extraction of remaining roots.~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues.~* Copious normal saline irrigation and curettage will be performed.~* In the study group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with cortico-cancellous allograft (MinerOss®, BioHorizons, USA)~* In the control group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with anorganic bovine bone mineral xenograft (Bio-Oss®, Geistlich, USA)
Study: NCT02887924

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neopuff; Fisher and Paykel, Auckland, New Zealand
Description: Following the oral and nasal aspirates, SLI at 25 cm H2O pressure will be applied for 15 seconds by using t-piece refreshing and binasal prongs and 5-cm nCPAP at H2O pressure will be applied.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neopuff; Fisher and Paykel, Auckland, New Zealand
Description: Following the oral and nasal aspirates, SLI at 25 cm H2O pressure will be applied for 15 seconds by using t-piece refreshing and binasal prongs and 5-cm nCPAP at H2O pressure will be applied.
Study: NCT01578317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 vaccine plus AS03 adjuvant
Description: H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 vaccine without adjuvant
Description: H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.
Study: NCT04487964

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Licorice extract
Description: LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.~Dose:~One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Licorice extract
Description: LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.~Dose:~One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour
Study: NCT04515420

Intervention type: DRUG
Intervention: noradrenaline
Description: noradrenaline infusion
Study: NCT01609582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-875 Placebo
Description: TAK-875 placebo-matching tablets
Study: NCT03129776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized 13C-Pyruvate
Description: The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG
Description: 18F-FDG is a radiopharmaceutical used in medical imaging. The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which is correlated with certain types of tissue metabolism, particularly in cancer cells. The participant will be injected with the study drug at a dose of 5 MBq/kg to a maximum of 500 MBq and then receive a PET scan.
Study: NCT04445233

Intervention type: DEVICE
Intervention: COVID-19 IgM-IgG Rapid Test
Description: Used to detect the IgG and IgM antibodies of the novel coronavirus in human whole blood (capillary or venous), serum, or plasma.

Intervention type: DEVICE
Intervention: COVID-19 IgM-IgG Rapid Test
Description: Used to detect the IgG and IgM antibodies of the novel coronavirus in human whole blood (capillary or venous), serum, or plasma.
Study: NCT03091868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Matching placebo capsules. Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Matching placebo capsules. Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Matching placebo capsules. Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Matching placebo capsules. Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® 100/25
Description: Single-dose of immediate release levodopa/carbidopa 100/25 mg consisted of 1 tablet of Sinemet® 100/25. Route of administration: Oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® 100/25
Description: Single-dose of immediate release levodopa/carbidopa 100/25 mg consisted of 1 tablet of Sinemet® 100/25. Route of administration: Oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® 100/25
Description: Single-dose of immediate release levodopa/carbidopa 100/25 mg consisted of 1 tablet of Sinemet® 100/25. Route of administration: Oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® 100/25
Description: Single-dose of immediate release levodopa/carbidopa 100/25 mg consisted of 1 tablet of Sinemet® 100/25. Route of administration: Oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comtan®
Description: Single-dose of entacapone 200 mg consisted of 1 tablet of Comtan®. Route of administration: Oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comtan®
Description: Single-dose of entacapone 200 mg consisted of 1 tablet of Comtan®. Route of administration: Oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comtan®
Description: Single-dose of entacapone 200 mg consisted of 1 tablet of Comtan®. Route of administration: Oral.
Study: NCT04311619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET-MR
Description: Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
Study: NCT02935231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health warning leaflet
Description: An A4 double-side color leaflet containing shocking pictures of diseases associated with smoking.
Study: NCT01356940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalfampridine ER
Description: dalfampridine ER 10mg bid for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dalfampridine ER
Description: dalfampridine ER 10mg bid for 4 weeks
Study: NCT02487719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia
Study: NCT03091868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comtan®
Description: Single-dose of entacapone 200 mg consisted of 1 tablet of Comtan®. Route of administration: Oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 25 mg
Description: BIA 6-512 capsules strengths 25 mg. Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 25 mg
Description: BIA 6-512 capsules strengths 25 mg. Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 100 mg
Description: BIA 6-512 capsules strengths 100 mg. Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 100 mg
Description: BIA 6-512 capsules strengths 100 mg. Oral administration.
Study: NCT03091933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLIDE
Description: Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line
Study: NCT05449522

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: High dose of vitamin D with 576,000 IU on the 3rd post-trauma day and 432,000 IU on the 10th post-trauma day (1,008,000 IU in total) is given orally or enterally via a feeding tube

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Medium-chain triglyceride (MCT)
Study: NCT02030938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SERI® Surgical Scaffold
Description: Standard revision augmentation (with or without implant exchange) with the adjunctive use of SERI® Surgical Scaffold placed intra- or extra-capsularly.
Study: NCT01138839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile water
Description: Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery
Study: NCT03398200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: The intervention consists of exposure to hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours, in a single see-through hyperbaric chamber, breathing 100% oxygen for 90 minutes while subjects are resting in supine position. During the 2 hours, there will be compression and decompression phases for 15 minutes each in which subjects will be breathing compressed environmental air (21% oxygen).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Hyperbaric Oxygen Therapy
Description: The reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell transplant.
Study: NCT02127593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)
Description: Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)
Description: Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)
Description: Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)
Description: Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.
Study: NCT01667692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin
Description: Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics.\[1\] It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithmycin
Description: Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
Study: NCT03311529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied Relaxation
Description: 10 training sessions (90 min. each) in Applied Relaxation (group format)
Study: NCT00121095

Intervention type: DRUG
Group type: OTHER
Intervention: Samarium Sm-153 lexidronam + Docetaxel
Description: 1 mCi/kg Sm153 + 75 mg/m2 docetaxel
Study: NCT03901885

Intervention type: OTHER
Group type: OTHER
Intervention: Female Sexual Function Index questionnaire
Description: Assessment of FSFI (Female Sexual Function Index) questionnaires preoperatively and postoperatively (4 months).
Study: NCT02349542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: One (1) 20 mL vial of 266 mg liposomal bupivacaine (3% (\~8mg free bupivacaine)) will be injected into each surgical (knee) site following simultaneous bilateral total knee arthroplasty. In addition, 30 mL of 0.25% bupivacaine (75 mg free bupivacaine) will be injected into each surgical (knee) site for a total of 83 mg free bupivacaine injected into each surgical (knee) site.
Study: NCT00560768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ovatio VR 6250 or DR6550
Description: The study requires the implantation of locally approved material:~* A right ventricular defibrillation lead~* In case of use of a dual chamber ICD a right atrial pacing lead~* A single chamber or dual chamber ICD manufactured by SORIN Group. At begin of the study this will be OVATIO VR model 6250 and OVATIO DR model 6550. Any new devices of same type manufactured by SORIN Group which will become locally approved during the conduction of the trial can be used in the study.~Holter recording will be performed with a market approved recording system allowing high resolution ECG recording compatible with the analysis software for TVar.
Study: NCT00498524

Intervention type: DEVICE
Intervention: ICD
Description: Received an ICD

Intervention type: DEVICE
Intervention: ICD
Description: Have not received an ICD
Study: NCT00992277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation and skin resurfacing
Study: NCT01132274

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency catheter ablation
Description: Conventional radiofrequency catheter ablation through fluoroscopic guidance of supraventricular arrhythmias.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Description: Radiofrequency catheter ablation through the non-fluoroscopic EnSite NavX mapping system (St.Jude Medical, St Paul, MN, USA) guidance.